The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas.
 
James J. Lee
Consulting or Advisory Role - Genentech
Research Funding - Merck
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Carolina BioOncology Institute; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Curis; Genentech/Roche; TopAlliance BioSciences Inc
Speakers' Bureau - Bristol-Myers Squibb; Dendreon; Genentech/Roche; Merck
Research Funding - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Corvus Pharmaceuticals; Curis; EMD Serono; Genentech/Roche; Incyte; Lilly/ImClone; Macrogenics; Seagen; Top Alliance BioScience
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
 
Manish R. Patel
Honoraria - Bristol-Myers Squibb; Exelixis; Genentech; Gilead Sciences; Guardant Health; Medivation
Speakers' Bureau - Bristol-Myers Squibb; Exelixis; Genentech; Gilead Sciences; Guardant Health; Medivation
 
Joshua Brody
Consulting or Advisory Role - Bristol-Myers Squibb; Celldex; Corvus Pharmaceuticals; Gilead Sciences; Janssen; Merck; Novartis; Pharmacyclics; Teva
Research Funding - Acerta Pharma; Celgene; Merck
 
Erika Paige Hamilton
Consulting or Advisory Role - Cascadian Therapeutics (Inst); Flatiron Health; Genentech/Roche (Inst); Pfizer (Inst)
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Cascadian Therapeutics (Inst); Curis (Inst); Genentech/Roche (Inst); Hutchison MediPharma (Inst); Kadmon (Inst); Lilly (Inst); Lycera (Inst); MedImmune (Inst); Medivation (Inst); Mersana (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); Rgenix (Inst); Stem CentRx (Inst); Syndax (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Verastem (Inst); Zymeworks (Inst)
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; Biothera; Celgene; Curegenix; Curis; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; GlaxoSmithKline; Hutchison MediPharma; Incyte; Jounce Therapeutics; Kolltan Pharmaceuticals; Lilly; MedImmune; Millennium; Novartis; OncoMed; Precision Oncology; Regeneron; Strategia Therapeutics; Syndax; Taiho Pharmaceutical; Tesaro; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Millennium; Sarah Cannon Research Institute
 
HongWei Wang
Employment - Curis
Stock and Other Ownership Interests - Curis
 
Lisa Adams
Employment - Curis
Leadership - Ribosepharm (I)
Stock and Other Ownership Interests - Curis; Ribosepharm (I)
 
Lucy Gong
Employment - Curis
Stock and Other Ownership Interests - Curis
 
Anna W Ma
Employment - Curis
 
Timothy Wyant
Employment - Curis
Stock and Other Ownership Interests - Curis
 
Adam Lazorchak
Employment - Curis
Stock and Other Ownership Interests - Curis
Research Funding - Curis
 
Shefali Agarwal
Employment - Curis
Stock and Other Ownership Interests - Curis
 
David P. Tuck
Employment - Curis
Leadership - Curis
Stock and Other Ownership Interests - Curis
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy